3-(4-fluorobenzyloxyimino)-2-(4-hydroxy-benzyl)-butyric acid methyl ester | 851180-91-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3-(4-fluorobenzyloxyimino)-2-(4-hydroxy-benzyl)-butyric acid methyl ester
• 英文别名: Methyl 3-[(4-fluorophenyl)methoxyimino]-2-[(4-hydroxyphenyl)methyl]butanoate；methyl 3-[(4-fluorophenyl)methoxyimino]-2-[(4-hydroxyphenyl)methyl]butanoate
• CAS: 851180-91-1
• 化学式: C₁₉H₂₀FNO₄
• 分子量: 345.371
• InChiKey: GESBMOTWSWDREX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  25
• 可旋转键数：
  8
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.26
• 拓扑面积：
  68.1
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  3-(4-fluorobenzyloxyimino)-2-(4-hydroxy-benzyl)-butyric acid methyl ester 在 sodium hydroxide 、 caesium carbonate 作用下， 以 四氢呋喃 、 甲醇 、 乙腈 为溶剂， 生成 (3Z)-3-{[(4-fluorophenyl)methoxy]imino}-2-({4-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]phenyl}methyl)butanoic acid
  参考文献：
  名称：

  Design and synthesis of oxime ethers of α-acyl-β-phenylpropanoic acids as PPAR dual agonists

  摘要：

  Oxime ethers of alpha-acyl-(3-phenylpropanoic acids were prepared to apply as PPAR alpha and gamma dual agonists. Among them, compound 111 proved to exhibit potent in vitro activities with EC50 of 19 and 13 nM in PPAR alpha and gamma, respectively. It showed better glucose lowering effects than rosiglitazone 1 and ameliorated the lipid profile like plasma triglyceride in dbldb mice model. (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2006.11.050
• 作为产物：
  描述：

  乙酰乙酸甲酯 在 哌啶 、 palladium dihydroxide 、 溶剂黄146 氢气 、 sodium acetate 作用下， 以 甲醇 、 乙酸乙酯 、 苯 为溶剂， 生成 3-(4-fluorobenzyloxyimino)-2-(4-hydroxy-benzyl)-butyric acid methyl ester
  参考文献：
  名称：

  Design and synthesis of oxime ethers of α-acyl-β-phenylpropanoic acids as PPAR dual agonists

  摘要：

  Oxime ethers of alpha-acyl-(3-phenylpropanoic acids were prepared to apply as PPAR alpha and gamma dual agonists. Among them, compound 111 proved to exhibit potent in vitro activities with EC50 of 19 and 13 nM in PPAR alpha and gamma, respectively. It showed better glucose lowering effects than rosiglitazone 1 and ameliorated the lipid profile like plasma triglyceride in dbldb mice model. (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2006.11.050

文献信息

• [EN] NOVEL COMPOUNDS AS AGONIST FOR PPAR GAMMA AND PPAR ALPHA, METHOD FOR PREPARATION OF THE SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME<br/>[FR] NOUVEAUX COMPOSES AGONISTES DE PPAR DOLLAR G(G) ET PPAR DOLLAR G(A), LEUR METHODE DE PREPARATION ET COMPOSITION PHARMACEUTIQUE LES CONTENANT
  申请人：LG LIFE SCIENCES LTD

  公开号：WO2005040127A1

  公开（公告）日：2005-05-06

  The present invention relates to novel compounds accelerating the activity of Peroxisome proliferator-activated receptor gamma (PPARϜ) and alpha (PPARα), processes of preparing the same, and pharmaceutical compositions containing the same as an active agent.

  本发明涉及一种新型化合物，可加速过氧化物酶体增殖物激活受体γ（PPARϜ）和α（PPARα）的活性，以及制备这种化合物的方法，以及含有该化合物作为活性成分的药物组合物。
• Design and synthesis of oxime ethers of α-acyl-β-phenylpropanoic acids as PPAR dual agonists
  作者：Hee Oon Han、Seung Hae Kim、Kyoung-Hee Kim、Gwong-Cheung Hur、Hyeon Joo Yim、Hee-Kyung Chung、Sung Ho Woo、Ki Dong Koo、Chang-Seok Lee、Jong Sung Koh、Geun Tae Kim

  DOI：10.1016/j.bmcl.2006.11.050

  日期：2007.2

  Oxime ethers of alpha-acyl-(3-phenylpropanoic acids were prepared to apply as PPAR alpha and gamma dual agonists. Among them, compound 111 proved to exhibit potent in vitro activities with EC50 of 19 and 13 nM in PPAR alpha and gamma, respectively. It showed better glucose lowering effects than rosiglitazone 1 and ameliorated the lipid profile like plasma triglyceride in dbldb mice model. (c) 2006 Elsevier Ltd. All rights reserved.